Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Epidermal growth factor receptor Stories

2014-04-09 10:43:30

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for...

New Combo Therapy Shows Promise For Cervical Cancer Treatment
2014-03-10 12:12:44

Bret Smith for redOrbit.com - Your Universe Online A team of Brazilian scientists has identified a promising new combination treatment that targets cervical cancer, according to a new report published in the journal Cancer. Patients with locally-advanced cervical cancer are typically prescribed cisplatin-based chemoradiation therapy (CRT), yet the benefits of this treatment have largely gone unresearched since the late 1990s, the study authors claimed. In search of a new treatment...

2013-12-18 09:46:31

The epidermal growth factor receptor (EGFR) is expressed in normal colonic cells and is activated by specific peptide growth factors that regulate cell proliferation, survival and differentiation. Increased expression and activation of the EGFR has been observed in the majority of colorectal carcinoma (CRC), suggesting that the EGFR pathway plays an important role in colon carcinogenesis. The monoclonal antibodies cetuximab and panitumumab are capable of blocking EGFR activity and have...

2013-12-09 12:25:58

Approximately Three-Quarters of Gilotrif Nonprescribers Anticipate Prescribing Gilotrif Within the Next Six Months, According to a New Report from BioTrends Research Group EXTON, Pa., Dec. 9, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, one month post-launch in the United States, more than a quarter of surveyed U.S. medical oncologists have prescribed Boehringer Ingelheim's...

2013-12-06 11:13:12

Researchers describe a novel mechanism by which glioblastoma tumors resist targeted therapies A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which glioblastoma (GBM), the most common kind of brain cancer, evades targeted therapies. Published in the current issue of the journal Science, the paper describes how GBM tumor cells essentially hide the signaling molecule targeted by such therapies, adding a layer of complexity to current models of drug resistance in...

2013-11-07 12:28:12

New targeted treatment delays lung cancer tumour progression and improves disease related symptoms versus standard chemotherapy(i) BURLINGTON, ON, Nov. 7, 2013 /CNW/ - Boehringer Ingelheim (Canada) Ltd. announced today that Health Canada has approved GIOTRIF(®) (afatinib) tablets for oral use, as a new treatment for Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic (including cytologically proven pleural effusion) adenocarcinoma of...

2013-10-21 16:25:45

GERMANTOWN, Maryland, and HILDEN, Germany, October 21, 2013 /PRNewswire/ -- - Collaboration to expand label of QIAGEN's FDA-approved therascreen(R) EGFR RGQ PCR Kit and creates framework for long term development and commercialization partnership - Companion diagnostic will run on QIAGEN's efficient Rotor-Gene Q MDx platform - QIAGEN adds to growing portfolio of companion diagnostics in...

2013-10-17 08:29:17

LAUSANNE, Switzerland, MECHELEN, Belgium and BARCELONA, Spain, October 17, 2013 /PRNewswire/ -- Today Biocartis and Hospital del Mar announced their licence agreement on the EGFR biomarker for colon cancer. This agreement enables Biocartis to develop a new colon cancer test, whereby a specific EGFR mutation can be rapidly and accurately detected in patients, which will enable doctors to recommend personalised therapy. Innovative platforms and tests for cancer diagnosis...

2013-10-16 04:21:50

SAN DIEGO, Calif., Oct. 16, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it will collaborate with a pharmaceutical company to evaluate Trovagene's proprietary, urine-based, cell-free DNA technology for the detection of certain epidermal growth factor receptor (EGFR) mutations associated with lung cancer. (Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO) "We are pleased to launch a...

2013-10-04 04:20:26

LAUSANNE, Switzerland, October 4, 2013 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology and companion diagnostics, will be presenting the 'JCA-Mauvernay Award' on October 5, to Doctors Issay Kitabayashi from Tokyo National Cancer Center Research Institute for his basic research on 'Molecular study of acute myeloid leukemia...